SOURCE: Ackrell Capital, LLC

Ackrell Capital, LLC Logo

February 24, 2016 08:00 ET

Ackrell Capital Publishes "U.S. Cannabis Investment Report 2016"

Includes the "Top 100 Private Cannabis Companies 2016" List & "The Green Field 2016" Cannabis Industry Landscape

SAN FRANCISCO, CA--(Marketwired - February 24, 2016) - Ackrell Capital, LLC today announced the publication of its inaugural "U.S. Cannabis Investment Report 2016." Ackrell Capital's 100-page investment report provides a comprehensive framework for analyzing the emerging investment opportunities in the U.S. cannabis industry.

The report covers key aspects of the cannabis industry, including: an overview of the basics of cannabis; the legislative landscape; market estimates; industry segmentation; the capital markets for cannabis companies; and industry risks.

Mike Ackrell, Founder of Ackrell Capital, stated: "The accelerating momentum toward cannabis legalization and the growth of this newly created market will result in the 'green gold rush' of our generation. A modern understanding of cannabis and a thorough analysis of both the opportunities and risks are paramount to evaluating the cannabis industry, which has the potential to reach more than 50 million consumers. Our report provides sophisticated investors with a foundation for evaluating if, when and how to invest in the cannabis industry."

Key Features and Highlights of the Investment Report include:

  • Inaugural list of the "Top 100 Private Cannabis Companies"
  • "The Green Field 2016" Cannabis Industry Landscape, featuring 400 cannabis companies
  • Why legalized recreational and medicinal cannabis use, currently at $4 billion annually, is estimated to grow to $9 billion annually in 2019
  • When and how the future market for cannabinoid-based pharmaceuticals may develop
  • Why the total cannabis consumer market may grow to $100 billion annually (assuming the end of federal prohibition by 2020) 

Shannon Soqui, Head of Cannabis Investment Banking at Ackrell Capital, stated: "Cannabinoid-based therapeutic applications have been identified for more than 40 medical conditions, including arthritis, cancer, chronic pain, epilepsy, HIV/AIDS and glaucoma. Due to the size of the treatment markets for these conditions, we are as excited for the prospects for the cannabinoid-based pharmaceuticals market as we are for the recreational market."

To receive a complimentary copy of the "U.S. Cannabis Investment Report 2016," the "Top 100 Private Cannabis Companies 2016" and "The Green Field 2016," please visit: www.ackrell.com/cannabis.

About Ackrell Capital
Ackrell Capital is a leading independent investment bank focused on emerging growth companies. During the last 25 years, Ackrell Capital's principals have completed more than 300 corporate finance and M&A transactions valued at more than $50 billion. Ackrell Capital's expertise includes private equity, mergers and acquisitions advisory services, private placements of debt or equity, and corporate development services. Our sector focus includes cannabis, consumer, technology, digital and other emerging growth industries. Ackrell Capital was founded in 2003 and is located in San Francisco, CA. Ackrell Capital is a member of FINRA and SIPC. To learn more, please visit us at www.ackrell.com.

This press release and the "U.S. Cannabis Investment Report 2016," the "Top 100 Private Cannabis Companies 2016" and "The Green Field 2016" have been prepared for informational purposes only and are not and should not be construed as an offer to sell securities or a solicitation of an offer to buy securities.

Image Available: http://www.marketwire.com/library/MwGo/2016/2/23/11G084254/Images/Photo_1-389991f1232ab965bdf3d4bcdc3e0ad1.jpg
Image Available: http://www.marketwire.com/library/MwGo/2016/2/23/11G084254/Images/Report_Cover-ba82f42b650cba8a87b39a50f373b4ad.jpg

Contact Information

  • For media inquiries, please contact:
    Ackrell Capital
    415-995-2000, x20
    info@ackrell.com